60 results
8-K
EX-1.1
KALV
KalVista Pharmaceuticals Inc
16 Feb 24
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
4:32pm
to such Pre-Funded Warrants as an offset effected by the Company of its claim for payment by the Underwriters to the Company for the Underwritten Shares
424B5
KALV
KalVista Pharmaceuticals Inc
16 Feb 24
Prospectus supplement for primary offering
4:29pm
will be required to pay a flat 30% tax on the gain derived from the sale, which gain may be offset by certain U.S. source capital losses (even though you
424B5
KALV
KalVista Pharmaceuticals Inc
14 Feb 24
Prospectus supplement for primary offering
5:13pm
described in (b) above, you will be required to pay a flat 30% tax on the gain derived from the sale, which gain may be offset by certain U.S. source
8-K
EX-99.1
n5ip9w
9 Sep 21
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
4:30pm
DEFA14A
0x6lsygssbc767iaxlgs
17 Aug 21
Additional proxy soliciting materials
4:21pm
8-K
EX-99.1
xhsmoik
13 Jul 21
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
4:20pm
8-K
EX-99.1
rpo0uf
11 Mar 21
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
5:15pm